Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA topoisomerase II is an essential ATP-dependent enzyme that manages the topology of double-stranded DNA by introducing transient double-strand breaks. This allows it to resolve supercoils, untangle intertwined chromosomes, and facilitate proper chromosome segregation during cell division. The human genome encodes two isoforms—TOP2A and TOP2B—with distinct but overlapping roles. Many anticancer drugs exploit this target by either stabilizing the normally transient cleavage complex formed between the enzyme and cleaved DNA (“topoisomerase poisons,” e.g., etoposide, doxorubicin), or by intercalating into the DNA itself to disrupt enzymatic activity. These mechanisms can lead to cytotoxic double-strand breaks if not properly repaired. Bacterial type II topoisomerases are also important antibiotic targets.
Inhibition of enzyme activity by stabilizing the covalent cleavage complex between topoisomerase II and DNA (“poisoning”); Intercalation into DNA to disrupt enzyme function.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA topoisomerase II (Top2).